Octaplaslg (Human Plasma Protein)

Human Plasma Protein, the active ingredient in Octaplaslg, is a plasma‑derived protein concentrate presented as a sterile liquid for intravenous use. It is used to support hemostasis in patients with multiple coagulation factor deficiencies, particularly during major surgery or trauma. GNH USA supplies Octaplaslg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Octaplaslg is a plasma‑derived protein concentrate that acts on the coagulation cascade to restore deficient clotting factors. - Massive transfusion protocols: provides balanced replacement of clotting factors to achieve hemostasis. - Liver transplantation: supports coagulation during the peri‑operative period. - Cardiac surgery with cardiopulmonary bypass: helps maintain adequate clotting function.

Adverse reactions to Octaplaslg are generally related to its plasma origin and infusion process.

Common Side Effects: - Fever: mild temperature elevation during or after infusion. - Chills: transient shaking sensation. - Headache: mild to moderate discomfort. - Nausea: occasional upset stomach. - Hypotension: slight drop in blood pressure. - Allergic rash: localized skin redness.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Transfusion‑related acute lung injury (TRALI): acute respiratory distress. - Severe hemolysis: rapid destruction of red blood cells. - Disseminated intravascular coagulation (DIC): uncontrolled clotting and bleeding. - Viral transmission: risk of blood‑borne pathogen infection. - Bacterial contamination: sepsis from contaminated product.

When using Octaplaslg, clinicians should observe several safety measures. - Verify patient identity and indication: confirm need for plasma‑derived factor replacement. - Monitor vital signs: watch for hypotension, fever, or allergic signs during infusion. - Assess coagulation status: perform baseline and post‑infusion labs. - Use compatible blood products: avoid mixing with incompatible plasma. - Document adverse events: report any reactions per pharmacovigilance guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplaslg may interact with other therapies that affect hemostasis or immune response.

Major Interactions (Avoid): - Anticoagulants (e.g., heparin, warfarin): may counteract clotting factor replacement. - High‑dose immunoglobulins: increase risk of volume overload.

Moderate Interactions (Monitor Closely): - Platelet inhibitors (e.g., aspirin, clopidogrel): require careful monitoring of bleeding risk. - Fibrinolytic agents (e.g., alteplase): may diminish clot stability. - Other plasma products: risk of cumulative volume overload. - Cytokine‑modulating drugs: potential for enhanced immune reactions.